|
| 36347257 | Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses. | Cell Host Microbe | 2023 |
| 37756379 | A MERS-CoV antibody neutralizes a pre-emerging group 2c bat coronavirus. | Sci Transl Med | 2023 |
| 37553406 | Self-assembling SARS-CoV-2 spike-HBsAg nanoparticles elicit potent and durable neutralizing antibody responses via genetic delivery. | NPJ Vaccines | 2023 |
| 37986823 | Mucosal Adenoviral-vectored Vaccine Boosting Durably Prevents XBB.1.16 Infection in Nonhuman Primates. | bioRxiv | 2023 |
| 37766115 | Enhancing Anti-SARS-CoV-2 Neutralizing Immunity by Genetic Delivery of Enveloped Virus-like Particles Displaying SARS-CoV-2 Spikes. | Vaccines (Basel) | 2023 |
| 37321165 | Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses. | Cell Host Microbe | 2023 |
| 37196074 | EV-D68 virus-like particle vaccines elicit cross-clade neutralizing antibodies that inhibit infection and block dissemination. | Sci Adv | 2023 |
| 37395646 | Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity. | J Virol | 2023 |
| 36087785 | Identification and functional analysis of histone 1.2-like in red sea bream (Pagrus major). | Dev Comp Immunol | 2023 |
| 33972947 | LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. | bioRxiv | 2022 |
| 35841885 | Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability. | Structure | 2022 |
| 35441178 | Broadly neutralizing antibodies target the coronavirus fusion peptide. | bioRxiv | 2022 |
| 35378757 | Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones. | bioRxiv | 2022 |
| 35568025 | LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. | Cell Rep | 2022 |
| 35447072 | mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. | Cell | 2022 |
| 36517467 | Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones. | Nat Commun | 2022 |
| 36516269 | A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primates. | Sci Transl Med | 2022 |
| 34921774 | Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. | Cell | 2022 |
| 35081298 | SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. | N Engl J Med | 2022 |
| 35324257 | Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529. | Science | 2022 |
| 34135892 | Sequence-Signature Optimization Enables Improved Identification of Human HV6-1-Derived Class Antibodies That Neutralize Diverse Influenza A Viruses. | Front Immunol | 2021 |
| 33494381 | Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses. | Vaccines (Basel) | 2021 |
| 33655252 | Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants. | bioRxiv | 2021 |
| 33907752 | Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates. | bioRxiv | 2021 |
| 33823129 | Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. | Immunity | 2021 |
| 33791692 | Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects. | bioRxiv | 2021 |
| 33821267 | Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants. | bioRxiv | 2021 |
| 33820835 | The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. | Sci Transl Med | 2021 |
| 33732238 | Functional Profiling of Antibody Immune Repertoires in Convalescent Zika Virus Disease Patients. | Front Immunol | 2021 |
| 34931200 | Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization. | medRxiv | 2021 |
| 34529476 | Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. | Science | 2021 |
| 34672695 | Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. | Science | 2021 |
| 34729558 | Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway. | bioRxiv | 2021 |
| 34519517 | Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. | Sci Transl Med | 2021 |
| 34461095 | SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity. | J Biol Chem | 2021 |
| 34426813 | Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates. | bioRxiv | 2021 |
| 34210892 | Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. | Science | 2021 |
| 34237283 | Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. | Cell Rep | 2021 |
| 34031659 | Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants. | bioRxiv | 2021 |
| 32384116 | Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus. | PLoS One | 2020 |
| 31801868 | Trypsin Treatment Unlocks Barrier for Zoonotic Bat Coronavirus Infection. | J Virol | 2020 |
| 33024963 | LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection. | bioRxiv | 2020 |
| 33097791 | A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone. | Sci Rep | 2020 |
| 33091382 | Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. | Cell Rep | 2020 |
| 32577634 | SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness. | bioRxiv | 2020 |
| 32596696 | Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. | bioRxiv | 2020 |
| 32877670 | Identification and Structure of a Multidonor Class of Head-Directed Influenza-Neutralizing Antibodies Reveal the Mechanism for Its Recurrent Elicitation. | Cell Rep | 2020 |
| 32676596 | A Platform Incorporating Trimeric Antigens into Self-Assembling Nanoparticles Reveals SARS-CoV-2-Spike Nanoparticles to Elicit Substantially Higher Neutralizing Responses than Spike Alone. | bioRxiv | 2020 |
| 32619441 | Convergent Evolution in Breadth of Two V<sub>H</sub>6-1-Encoded Influenza Antibody Clonotypes from a Single Donor. | Cell Host Microbe | 2020 |
| 32756549 | SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. | Nature | 2020 |